Skip to content
DataLookout
Menu

DEVOTENCT07734064

A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 4 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Start date pushed from Aug 10, 2026 to Aug 14, 2026
    • Study sites: 3 to 4
  2. Notable Eligibility criteria expanded, about 35 words
    • Study sites: 1 to 3
    • Secondary endpoints: details revised at 1 of 14 entries
  3. Notable Recruitment opened
    • Study sites: 0 to 1
    • Start date changed from estimate of Jul 31, 2026 to Aug 10, 2026
    v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of participants with treatment-emergent adverse events (TEAEs)
Timeframe: Up to 52 weeks
Number of participants with serious adverse events (SAEs)
Timeframe: Up to 52 weeks
Number of participants with adverse events of special interest (AESIs)
Timeframe: Up to 52 weeks
Number of participants with greater than or equal to 15 letter loss in best corrected visual acuity (BCVA) from baseline
Timeframe: Up to 52 weeks
Number of participants with significant changes in vital signs from baseline
Timeframe: Up to 52 weeks
Number of participants with significant changes in laboratory values from baseline
Timeframe: Up to 52 weeks

Secondary (14)

Change from baseline in BCVA
Change from baseline in low luminance visual acuity (LLVA)
Change from baseline in Minnesota Reading Acuity Chart (MNREAD) parameters
Change from baseline in mesopic macular sensitivity
Change from baseline in central retinal thickness (CRT)
Show 9 moreShow less
Change from baseline in total photoreceptor thickness (TPT)
Change from baseline in ellipsoid zone (EZ) integrity
Change from baseline in outer nuclear layer (ONL)
Change from baseline in retinal pigment epithelium (RPE) integrity
Change from baseline in questionably decreased autofluorescence (QDAF)
Change from baseline in definitely decreased autofluorescence (DDAF)
Change from baseline in anti-human leukocyte antigen (HLA) antibodies
Change from baseline in anti herpes simplex virus thymidine kinase (HSV- TK) antibodies
Change from baseline in cytokines

Arms and interventions

Part 1 Dose Escalation: Adult - Low DoseExperimental

Adult participants will receive a single low dose of ASP2020 on Day 1, administered by subretinal injection as part of a surgical procedure, followed by triamcinolone acetonide as adjunct treatment by posterior sub-Tenon injection.

Part 1 Dose Escalation: Adult - High DoseExperimental

Adult participants will receive a single high dose of ASP2020 on Day 1, administered by subretinal injection as part of a surgical procedure, followed by triamcinolone acetonide as adjunct treatment by posterior sub-Tenon injection.

Part 1 Dose Escalation: Adolescent - Low DoseExperimental

Adolescent participants will receive single low dose of ASP2020 by subretinal injection on Day 1 followed by triamcinolone acetonide as adjunct treatment by posterior sub-Tenon injection.

Part 1 Dose Escalation: Adolescent - High DoseExperimental

Adolescent participants will receive single high dose of ASP2020 by subretinal injection on Day 1 followed by triamcinolone acetonide as adjunct treatment by posterior sub-Tenon injection.

Part 2 Dose Expansion: Adult with macular dystrophiesExperimental

Adult participants will receive single optimal dose of ASP2020 established in part 1 by subretinal injection on Day 1 followed by triamcinolone acetonide as adjunct treatment by posterior sub-Tenon injection.

Part 2 Dose Expansion: Pediatric with macular dystrophiesExperimental

Pediatric participants will receive single optimal dose of ASP2020 established in part 1 by subretinal injection on Day 1 followed by triamcinolone acetonide as adjunct treatment by posterior sub-Tenon injection.

Drugs: ASP2020

Sites

4 sites in 1 country